search
Back to results

Treatment of Chronic and Non-Chronic Wounds in Patients With Recessive Dystrophic Epidermolysis Bullosa Using Helicoll Collagen Dressings Versus Standard of Care

Primary Purpose

Epidermolysis Bullosa Dystrophica, Epidermolysis Bullosa

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Helicoll
Standard of Care Dressings
Sponsored by
Stanford University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Epidermolysis Bullosa Dystrophica

Eligibility Criteria

7 Years - undefined (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion criteria:

  1. Written consent must be obtained from subjects over age 18, or from a parent or legally authorized representative if subject is under 18. Assent will be obtained from subjects age 7 - 17.
  2. Subjects with a clinical diagnosis of RDEB by a dermatologist.
  3. Have at least three target wounds that meet the following criteria:

    • One chronic wound, of approximately 6 months or more duration. If the subject has an additional chronic wound of similar size and duration, this additional wound will be treated with standard dressings and followed in the study. A wound in an area that consistently heals and then breaks down again will be considered a chronic wound.
    • Two non-chronic wounds, of approximately 3 months or less duration, of similar size, and able to be dressed separately. Both wounds should have approximately the same duration.

    All wounds must be:

    • Open, and not scabbed or crusted over
    • Not actively infected
    • Not requiring surgical intervention
  4. A parent or legally authorized representative must be willing and able to ensure subject is present for all required study visits (for minor subjects).
  5. The subject or caregiver (or a parent or legally authorized representative for subjects under 18) must be able to follow instructions.
  6. Subject must be age 7 or older.

Exclusion criteria:

  1. Inability to travel to Stanford for study visits.
  2. Complicating illness as determined by study investigators to be exclusionary including any infection requiring systemic antibiotics.
  3. Presence or history of squamous cell carcinoma at target wound site.
  4. Known bovine (cow) or ovine (sheep) sensitivity.
  5. Therapy with an investigational agent during the study.

Sites / Locations

  • Stanford School of Medicine

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Helicoll

Arm Description

Helicoll will be applied to one chronic wound (approximately 6 months or more duration). Wound designations of "control" or "Helicoll" were placed in a sealed envelope prior to study start. When a subject was enrolled, wounds were identified as "A" or "B". Then the envelope was opened which designated whether A or B would receive control or Helicoll.

Outcomes

Primary Outcome Measures

Percentage of Wound Surface Area Change From Baseline to Week 8
Change was assessed in terms of wound surface area, as measured using the ARANZ camera. Week 8 surface area measurement was compared to baseline surface area measurement and percentage in size change was calculated.

Secondary Outcome Measures

Full Information

First Posted
October 25, 2012
Last Updated
April 1, 2016
Sponsor
Stanford University
search

1. Study Identification

Unique Protocol Identification Number
NCT01716169
Brief Title
Treatment of Chronic and Non-Chronic Wounds in Patients With Recessive Dystrophic Epidermolysis Bullosa Using Helicoll Collagen Dressings Versus Standard of Care
Official Title
Treatment of Chronic and Non-Chronic Wounds in Patients With Recessive Dystrophic Epidermolysis Bullosa Using Helicoll Collagen Dressings Versus Standard of Care
Study Type
Interventional

2. Study Status

Record Verification Date
April 2016
Overall Recruitment Status
Completed
Study Start Date
October 2012 (undefined)
Primary Completion Date
November 2013 (Actual)
Study Completion Date
November 2013 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Stanford University

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this study is to test the effectiveness of Helicoll (a collagen wound dressing) in treating chronic and non-chronic wounds of recessive dystrophic epidermolysis bullosa (RDEB) patients. Helicoll will be compared to standard wound dressings.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Epidermolysis Bullosa Dystrophica, Epidermolysis Bullosa

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
10 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Helicoll
Arm Type
Experimental
Arm Description
Helicoll will be applied to one chronic wound (approximately 6 months or more duration). Wound designations of "control" or "Helicoll" were placed in a sealed envelope prior to study start. When a subject was enrolled, wounds were identified as "A" or "B". Then the envelope was opened which designated whether A or B would receive control or Helicoll.
Intervention Type
Device
Intervention Name(s)
Helicoll
Intervention Description
Helicoll Collagen I Wound Dressing
Intervention Type
Device
Intervention Name(s)
Standard of Care Dressings
Intervention Description
Standard of Care wound dressings (e.g. Vaseline gauze)
Primary Outcome Measure Information:
Title
Percentage of Wound Surface Area Change From Baseline to Week 8
Description
Change was assessed in terms of wound surface area, as measured using the ARANZ camera. Week 8 surface area measurement was compared to baseline surface area measurement and percentage in size change was calculated.
Time Frame
Baseline and Week 8

10. Eligibility

Sex
All
Minimum Age & Unit of Time
7 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion criteria: Written consent must be obtained from subjects over age 18, or from a parent or legally authorized representative if subject is under 18. Assent will be obtained from subjects age 7 - 17. Subjects with a clinical diagnosis of RDEB by a dermatologist. Have at least three target wounds that meet the following criteria: One chronic wound, of approximately 6 months or more duration. If the subject has an additional chronic wound of similar size and duration, this additional wound will be treated with standard dressings and followed in the study. A wound in an area that consistently heals and then breaks down again will be considered a chronic wound. Two non-chronic wounds, of approximately 3 months or less duration, of similar size, and able to be dressed separately. Both wounds should have approximately the same duration. All wounds must be: Open, and not scabbed or crusted over Not actively infected Not requiring surgical intervention A parent or legally authorized representative must be willing and able to ensure subject is present for all required study visits (for minor subjects). The subject or caregiver (or a parent or legally authorized representative for subjects under 18) must be able to follow instructions. Subject must be age 7 or older. Exclusion criteria: Inability to travel to Stanford for study visits. Complicating illness as determined by study investigators to be exclusionary including any infection requiring systemic antibiotics. Presence or history of squamous cell carcinoma at target wound site. Known bovine (cow) or ovine (sheep) sensitivity. Therapy with an investigational agent during the study.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Alfred Lane, MD
Organizational Affiliation
Stanford University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Stanford School of Medicine
City
Stanford
State/Province
California
ZIP/Postal Code
94305
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Treatment of Chronic and Non-Chronic Wounds in Patients With Recessive Dystrophic Epidermolysis Bullosa Using Helicoll Collagen Dressings Versus Standard of Care

We'll reach out to this number within 24 hrs